📣 VC round data is live. Check it out!

Claritev Valuation Multiples

Discover Claritev's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Weave Communications, Heren Health, GPI Group, Veradigm and more.

Claritev Overview

About Claritev

Claritev Corp is a healthcare technology, data, and insights company focused on improving transparency, affordability, and quality. The company provides tech-enabled solutions and services to interpret clients' needs and customize solutions that combine its payment integrity, network-based, and analytics-based services. The Company's focus is being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the U.S. healthcare industry.


Founded

2019

HQ

United States

Employees

2.7K

Financials (LTM)

Revenue: $976M
EBITDA: $605M

EV

$5B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Claritev Financials

Claritev reported last 12-month revenue of $976M and EBITDA of $605M.

In the same LTM period, Claritev generated $719M in gross profit, $605M in EBITDA, and had net loss of ($276M).

Revenue (LTM)


Claritev P&L

In the most recent fiscal year, Claritev reported revenue of $965M and EBITDA of $603M.

Claritev is unprofitable as of last fiscal year, with gross margin of 67%, EBITDA margin of 62%, and net margin of (29%).

See analyst estimates for Claritev
LTMLast FY202320242025202620272028
Revenue$976M$965M$962M$931M$965M
Gross Profit$719M$649M$726M$627M$649M
Gross Margin74%67%76%67%67%
EBITDA$605M$603M$652M($1B)$467M
EBITDA Margin62%62%68%(108%)48%
EBIT Margin8%5%18%11%5%
Net Profit($276M)($284M)($92M)($2B)($284M)
Net Margin(28%)(29%)(10%)(177%)(29%)
Net Debt-$5B---

Financial data powered by Morningstar, Inc.

Claritev Stock Performance

Claritev has current market cap of $483M, and enterprise value of $5B.

Market Cap Evolution


Claritev's stock price is $28.34.

Claritev share price increased by 12.8% in the last 30 days, and decreased by 37.1% in the last year.

Claritev has an EPS (earnings per share) of $-16.68.

See more trading valuation data for Claritev
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$5B$483M5.0%12.8%73.4%-37.1%$-16.68

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Claritev Valuation Multiples

Claritev trades at 5.3x EV/Revenue multiple, and 8.6x EV/EBITDA.

See NTM and 2027E valuation multiples for Claritev

EV / Revenue (LTM)


Claritev Financial Valuation Multiples

As of June 3, 2026, Claritev has market cap of $483M and EV of $5B.

Claritev has a P/E ratio of (1.8x).

LTMLast FY202320242025202620272028
EV/Revenue5.3x5.4x5.4x5.6x5.4x
EV/EBITDA8.6x8.6x8.0x(5.2x)11.1x
EV/EBIT65.8x115.3x30.6x52.5x115.3x
EV/Gross Profit7.2x8.0x7.2x8.3x8.0x
P/E(1.8x)(1.7x)(5.3x)(0.3x)(1.7x)
EV/FCFn/mn/m82.6xn/mn/m

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Claritev Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Claritev Margins & Growth Rates

Claritev grew revenue by 3% and EBITDA by 1% in the last fiscal year.

In the most recent fiscal year, Claritev reported gross margin of 67%, EBITDA margin of 62%, and net margin of (29%).

See estimated margins and future growth rates for Claritev

Claritev Margins

Last FY202420252026202720282029
Gross Margin67%67%67%74%
EBITDA Margin62%(108%)48%61%
EBIT Margin5%11%5%15%
Net Margin(29%)(177%)(29%)(27%)
FCF Margin(1%)(1%)(1%)0%

Claritev Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth3%(3%)4%3%
Gross Profit Growth12%(14%)3%12%
EBITDA Growth1%(255%)(146%)30%
EBIT Growth228%(42%)(54%)228%
Net Profit Growth(7%)1695%(83%)(7%)
FCF Growth(138%)(117%)17%(138%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Claritev Operational KPIs

Claritev's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.3M for the same period.

Claritev's Rule of 40 is 64% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Claritev's Rule of X is 68% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Claritev
LTMLast FY202320242025202620272028
Rule of 4065%64%---
Bessemer Rule of X70%68%---
Revenue per Employee-$0.4M---
Opex per Employee-$0.3M---
G&A Expenses to Revenue22%22%14%10%16%
Opex to Revenue95%97%58%57%63%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Weave Communications1.9x1.8x58.8x39.0x
Heren Health6.5x-34.9x-
GPI Group1.4x1.3x6.7x6.4x
Veradigm-0.5x-3.4x
Guiyang Longmaster10.8x-85.6x-
Shanghai Wondertek11.0x-105.5x-
Artrya24054.7x164.7x(50.1x)(34.8x)
Medley Inc.1.9x1.7x14.5x13.4x

This data is available for Pro users. Sign up to see all Claritev competitors and their valuation data.

Start Free Trial

Claritev VC Funding History

Before going public, Claritev raised $77M in total equity funding, across 1 round.


Claritev Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Nov-25Secondary - public-$77M--

Acquisitions by Claritev

Claritev has acquired 3 companies to date.

Last acquisition by Claritev was on May 9th 2023. Claritev acquired Benefits Science for $160M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Claritev

Benefits Science
Discovery Health Partners
HST
Description
Benefits Science is a Denver-based software provider offering predictive analytics for self-insured health plans. The platform employs machine learning algorithms and actuarial models to forecast claims, recommend optimized medical benefits, and assess plan performance against employer budgets. Clients include large self-funded employers and TPAs who use its tools to cut costs by up to 15 percent while improving member care quality. Founded in 2017, Benefits Science integrates with claims data from major carriers like Cigna and Blue Cross Blue Shield.
Discovery Health Partners is a provider of payment integrity and revenue optimization software for health insurance payers. Franklin, Tennessee-headquartered, it deploys analytics platforms for claims auditing, overpayment recovery, DRG validation, and government program reimbursements including Medicare Advantage and Medicaid.
HST is a provider of value-based payment technologies for healthcare since 2009, headquartered in the United States. It offers pricing benchmarks and analytics software to determine medical service values, supporting insurers and employers with cost transparency tools for surgical procedures, imaging, and outpatient care.
HQ CountryUnited StatesUnited StatesUnited States
HQ City
Boston, MA
Chicago, IL
Los Angeles, CA
Deal Date9 May 202321 Jan 202110 Nov 2020
Valuation$160M$155M$140M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Claritev acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Claritev

Claritev has invested in 2 companies to date.

Latest investment by Claritev was on June 16th 2022. Claritev invested in Abacus Insights in their $41M Series C round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Claritev

Abacus Insights
DocASAP
Description
-
DocASAP is a Virginia-headquartered patient engagement platform founded in 2012, serving health systems, payers, and physician groups. It facilitates intelligent provider-patient matching for streamlined access, care compliance, and population health management, fostering payer-provider connections to lower costs and enhance outcomes.
HQ CountryUnited StatesUnited States
HQ City
-
Washington, DC
Deal Date16 Jun 20225 Sep 2013
RoundSeries CSeed
Raised$41M$800K
Investors.406 Ventures; Claritev; CRV; Echo Health Ventures; Horizon Healthcare Services; The Blue Venture FundBlueprint Health; Claritev
Valuationundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Claritev investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Claritev

When was Claritev founded?Claritev was founded in 2019.
Where is Claritev headquartered?Claritev is headquartered in United States.
How many employees does Claritev have?As of today, Claritev has over 2K employees.
Who is the CEO of Claritev?Claritev's CEO is Travis S. Dalton.
Is Claritev publicly listed?Yes, Claritev is a public company listed on NYSE.
What is the stock symbol of Claritev?Claritev trades under CTEV ticker.
When did Claritev go public?Claritev went public in 2020.
Who are competitors of Claritev?Claritev main competitors include Weave Communications, Heren Health, GPI Group, Veradigm, Guiyang Longmaster, Shanghai Wondertek, Artrya, Medley Inc., WingArc1st, Beijing Sunwayworld.
What is the current market cap of Claritev?Claritev's current market cap is $483M.
What is the current revenue of Claritev?Claritev's last 12 months revenue is $976M.
What is the current revenue growth of Claritev?Claritev revenue growth (NTM/LTM) is 3%.
What is the current EV/Revenue multiple of Claritev?Current revenue multiple of Claritev is 5.3x.
What is the current EBITDA of Claritev?Claritev's last 12 months EBITDA is $605M.
What is Claritev's EBITDA margin?Claritev's last 12 months EBITDA margin is 62%.
What is the current EV/EBITDA multiple of Claritev?Current EBITDA multiple of Claritev is 8.6x.
What is the current FCF of Claritev?Claritev's last 12 months FCF is ($5M).
What is Claritev's FCF margin?Claritev's last 12 months FCF margin is (1%).
What is the current EV/FCF multiple of Claritev?Current FCF multiple of Claritev is (1012.2x).
How many companies Claritev has acquired to date?As of June 2026, Claritev has acquired 3 companies.
What was the largest acquisition by Claritev?$160M acquisition of Benefits Science on 9th May 2023 was the largest M&A Claritev has done to date.
What companies Claritev acquired?Claritev acquired Benefits Science, Discovery Health Partners, and HST.
In how many companies Claritev has invested to date?As of June 2026, Claritev has invested in 2 companies.
What was the last Claritev investment?On 16th June 2022 Claritev invested in Abacus Insights, participating in a $41M Series C round, alongside .406 Ventures, CRV, Echo Health Ventures, Horizon Healthcare Services, and The Blue Venture Fund.
In what companies Claritev invested in?Claritev invested in Abacus Insights and DocASAP.

See public comps similar to Claritev

Lists including Claritev

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial